Background
IDO regulatory and effector signaling pathways
Upstream regulators
Downstream effectors
Role of the IDO1 pathway in cancers
IDO1 ablates T effector cells and promotes the induction of Treg cells and MDSCs in the tumor microenvironment
IDO1 and immune checkpoint inhibitors
Tumor neovascularization
IDO1 and the gut microbiome
IDO1 inhibitors in preclinical development and clinical trials
Drug | Strategies | Tumor type | Phase | Clinical efficacy | Safety (% patients) | Trial number | Status |
---|---|---|---|---|---|---|---|
Indoximod | Single agent | Metastatic or refractory solid tumors | I | NR | NR | NCT00739609 | Terminated |
Metastatic or refractory solid tumors | I | ORR 10% (5/48) | Fatigue (56.3%), anemia (37.5%), anorexia (37.5%) dyspnea (35.4%) cough (33.3%) nausea (29.2%) | NCT00567931 | Completed | ||
Docetaxel | Metastatic solid tumors | I | 4/22PRs, 9/22 SD, and 9/22 PD | Fatigue (58.6%) anemia (51.7%) hyperglycemia (48.3%), infection (44.8%), nausea (41.4%) | NCT01191216 | Completed | |
Temozolomide/bevacizumab | Primary malignant brain tumors | I/II | NR | NR | NCT02052648 | Recruiting | |
Temozolomide | Progressive primary malignant brain tumors | I | NCT02502708 | Recruiting | |||
Docetaxel/paclitaxel | Metastatic breast cancer | II | NCT01792050 | Unknown | |||
Nab-Paclitaxel/gemcitabine | Metastatic pancreatic cancer | I/II | ORR 11/30 (37%) | 1/30 (colitis) | NCT02077881 | Recruiting | |
Idarubicin/cytarabine | Acute myeloid leukemia | I/II | NCT02835729 | Recruiting | |||
Adenovirus-p53 transduced dendritic cell (DC) vaccine | Metastatic breast cancer | I/II | Chemosensitization effect, median PFS 13.3 weeks and median OS 20.71 weeks. 9/22 patients benefitted from chemotherapy after vaccination. | Most common grade 1–2 (fatigue, anemia, transient lymphopenia, nausea, anorexia) | NCT01042535 | Completed | |
Sipuleucel-T | Refractory metastatic prostate cancer | II | NR | NR | NCT01560923 | Active, not recruiting | |
Tergenpumatucel-L/docetaxel | Advanced previously treated non-small cell lung cancer | I/II | NCT02460367 | Unknown | |||
Ipilimumab/nivolumab/pembrolizumab | Metastatic melanoma | II/ III | NCT03301636 | Recruiting | |||
Epacadostat | Single agent | Advanced malignancy | I/II | NR | Fatigue, nausea, decreased appetite, vomiting, constipation, abdominal pain, diarrhea, dyspnea, back pain, cough | NCT01195311 | Completed |
Solid tumor | I | NCT03471286 | Not yet recruiting | ||||
Myelodysplastic syndromes | II | NCT01822691 | Completed | ||||
Fludarabine/cyclophosphamide/NK cells/IL-2 | Recurrent ovarian, fallopian tube, and primary peritoneal cancer | I | NCT02118285 | Completed | |||
Tamoxifen | Ovarian cancer genitourinary tumors | II | Median PFS, 3.75 months | Fatigue (36.4%) rash (18.2%) pruritus (9.1%) | NCT01685255 | Terminated | |
Azacitidine + pembrolizumab | Advanced solid tumors | I/II | NR | NR | NCT02959437 | Recruiting | |
MELITAC 12.1 peptide vaccine | Stage III-IV melanoma | II | NR | NR | NCT01961115 | Active, not recruiting | |
DPX-survivac/cyclophosphamide | Ovarian cancer | I | NR | NR | NCT02785250 | Recruiting | |
ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine | Ovarian, fallopian tube, or primary peritoneal cancer | I/II | NR | NR | NCT01982487 | Withdrawn | |
DEC-205/NY-ESO-1 fusion protein CDX-1401/poly ICLC | Ovarian, fallopian tube, or primary peritoneal cancer | I/II | NR | NR | NCT02166905 | Recruiting | |
CRS-207/pembrolizumab | Metastatic pancreas cancer, platinum-resistant ovarian, fallopian, or peritoneal cancer | II,I/II | NR | NR | NCT03006302 | Recruiting active, not recruiting | |
NCT02575807 | |||||||
Atezolizumab | Non-small cell lung cancer and urothelial carcinoma | I | NR | NR | NCT02298153 | Terminated | |
Durvalumab | Advanced solid tumor | I/II | NR | NR | NCT02318277 | Recruiting | |
Ipilimumab | Melanoma | I/II | NCT01604889 | Terminated | |||
Nivolumab/ipilimumab/lirilumab | Solid tumors | I/II | NCT03347123 | Recruiting | |||
Nivolumab/chemotherapy | Advanced cancers | I/II | ORR 75%(melanoma) 11% (ovarian) 4% (colorectal) | Rash (10% and 12% in epacadostat 100 and 300 mg subgroups) | NCT02327078 | Recruiting | |
Pembrolizumab/chemotherapy | Advanced solid tumors | I, I/II | NR | NR | NCT02862457 | Recruiting | |
NCT03085914 | Recruiting | ||||||
pembrolizumab | Solid tumors, thymic carcinoma, sarcoma, junction or gastric cancer, lung cancer, urothelial cancer, metastatic melanoma, and others. | I, I/II, III | Melanoma (ORR 57% and DCR 86%), Renal cell carcinoma (ORR 40% and DCR 80%) | Fatigue, diarrhea, rash, arthralgia, and nausea | NCT02178722 | Recruiting | |
NCT02364076 | Recruiting | ||||||
NCT03414229 | Recruiting | ||||||
NCT03196232 | Recruiting | ||||||
NCT03322540 | Recruiting | ||||||
NCT03361865 | Recruiting | ||||||
Pembrolizumab | Melanoma | III | NCT02752074 | Halted | |||
Navoximod | Single agent | Advanced solid tumors | I | NR | NR | NCT02048709 | Completed |
Atezolizumab | Solid tumors | I | NCT02471846 | Active, not recruiting | |||
PF-06840003 | Single agent | Malignant gliomas | I | NCT02764151 | Active, not recruiting | ||
BMS-986205 | Nivolumab | Melanoma advanced cancers | III, I/II | NR | 3/42 patients with grade 3 autoimmune hepatitis | NCT03329846 | Recruiting |
NCT03192943 | Recruiting | ||||||
Nivolumab/ipilimumab | Advanced cancer melanoma non-small cell lung cancer | I/II | ORR 32%(bladder cancer) 14%(cervical cancer) PD-L1 > 1%: 46% (bladder cancer)and 25% (cervical cancer) | Fatigue (18.2% nausea (18.2%) decreased appetite (13.6%) vomiting (6.8%) | NCT02658890 | Recruiting | |
Nivolumab/ipilimumab/relatlimab | Advanced gastric cancer, advanced renal cell carcinoma, advanced cancer | II, I/II | NR | NR | NCT02935634 | Recruiting | |
NCT02996110 | Recruiting | ||||||
NCT03459222 | Not yet recruiting | ||||||
NCT03335540 | Recruiting | ||||||
Nivolumab/cetuximab/chemotherapy | Head and neck cancer | III | NR | NR | NCT03386838 | Halted | |
Nivolumab/chemotherapy | Lung cancer | III | NCT03417037 | Halted |